Sfoglia per Autore "Gerou, S."
Items 1-3 di 3
-
Acute changes in serum osteoprotegerin and receptor activator for nuclear factor-kappa B ligand levels in women with established osteoporosis treated with teriparatide
Anastasilakis, A. D.; Goulis, D. G.; Polyzos, S. A.; Gerou, S.; Pavlidou, V.; Koukoulis, G.; Avramidis, A. (2008)Objective: The mechanisms regulating the anabolic response of the skeleton to intermittent exogenous parathyroid hormone (PTH) administration are not fully elucidated. The aim of this prospective study was to evaluate the ... -
Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial
Anastasilakis, A. D.; Goulis, D. G.; Polyzos, S. A.; Gerou, S.; Koukoulis, G. N.; Efstathiadou, Z.; Kita, M.; Avramidis, A. (2008)Aims: We aimed to compare the effect of risedronate (RIS) and teriparatide (TPTD) (recombinant human parathyroid hormone 1-34) on bone turnover markers in women with postmenopausal osteoporosis. Methods: Forty-four Caucasian ... -
Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: A randomized, controlled trial
Anastasilakis, A. D.; Goulis, D. G.; Polyzos, S. A.; Gerou, S.; Koukoulis, G.; Kita, M.; Avramidis, A. (2008)Risedronate and teriparatide have opposite actions on the osteoblast-osteoclast dipole and are expected to influence the RANK/RANKL/ osteoprotegerin (OPG) system. We aimed to evaluate changes in serum OPG and RANKL after ...